Ascentage Pharma Group International (AAPG)
Ascentage Pharma Group International is a clinical-stage biotechnology company developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases, with a focus on targeted inhibitors such as HQP1351 for BCR-ABL1 mutants and a pipeline including oral inhibitors for hematologic malignancies, solid tumors, and advanced solid tumors. The company also engages in medical research, clinical development, and collaborations with biotechnology, pharmaceutical companies, and research institutions.
Company Info
Highlights
$6.35B
-$0.17
$16.50 - $43.58
0.58
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Ascentage Pharma Group International, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading data...
Returns By Period
AAPG
- YTD
- N/A
- 1M
- 21.36%
- 6M
- N/A
- 1Y
- N/A
- 3Y*
- N/A
- 5Y*
- N/A
- 10Y*
- N/A
^GSPC (Benchmark)
- YTD
- 6.43%
- 1M
- 4.73%
- 6M
- 7.43%
- 1Y
- 11.48%
- 3Y*
- 17.91%
- 5Y*
- 14.47%
- 10Y*
- 11.49%
Monthly Returns
The table below presents the monthly returns of AAPG, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
Based on daily data since Jan 2025, the average daily return (also called the expected return) is 0.78%, while the average monthly return is 13.48%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 1.73% | 7.64% | 15.34% | 11.30% | -0.12% | 61.37% | 3.47% | 134.41% |
Risk-Adjusted Performance
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Ascentage Pharma Group International (AAPG) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Ascentage Pharma Group International. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Ascentage Pharma Group International was 23.28%, occurring on Apr 10, 2025. Recovery took 8 trading sessions.
The current Ascentage Pharma Group International drawdown is 10.76%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -23.28% | Apr 4, 2025 | 5 | Apr 10, 2025 | 8 | Apr 23, 2025 | 13 |
| -14.22% | Apr 28, 2025 | 14 | May 15, 2025 | 6 | May 23, 2025 | 20 |
| -13.23% | Feb 24, 2025 | 23 | Mar 26, 2025 | 2 | Mar 28, 2025 | 25 |
| -8.68% | Feb 11, 2025 | 3 | Feb 13, 2025 | 3 | Feb 19, 2025 | 6 |
| -7.85% | May 27, 2025 | 4 | May 30, 2025 | 2 | Jun 3, 2025 | 6 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Ascentage Pharma Group International over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Ascentage Pharma Group International is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for AAPG relative to other companies in the Biotechnology industry. Currently, AAPG has a P/S ratio of 7.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for AAPG in comparison with other companies in the Biotechnology industry. Currently, AAPG has a P/B value of 60.6. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |